Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

Schwaederle, Maria, Parker, Barbara A., Schwab, Richard B., Daniels, Gregory A., Piccioni, David E., Kesari, Santosh, Helsten, Teresa L., Bazhenova, Lyudmila A., Romero, Julio, Fanta, Paul T., Lippman, Scott M., Kurzrock, Razelle·2016·Molecular Cancer Therapeutics

Abstract

By profiling their patients' tumors, oncologists now have the option to use molecular results to match patients with drug(s) based on specific biomarkers. In this observational study, 347 patients with solid advanced cancers and next-generation sequencing (NGS) results were evaluated. Outcomes for patients who received a “matched” versus “unmatched” therapy following their NGS results were compared. Eighty-seven patients (25%) were treated with a “matched” therapy, 93 (26.8%) with an “unmatched” therapy. More patients in the matched group achieved stable disease (SD) ≥ 6 months/partial response (PR)/complete response (CR), 34.5% vs. 16.1%, (P ≤ 0.020 multivariable or propensity score methods). Matched patients had a longer median progression-free survival (PFS; 4.0 vs. 3.0 months, P = 0.039 in the Cox regression model). In analysis using PFS1 (PFS on the prior line of therapy) as a comparator to PFS after NGS, as expected, the unmatched group demonstrated a PFS2 significantly shorter than PFS1 (P = 0.009); however, this shortening was not observed in the matched patients (P = 0.595). Furthermore, 45.3% of the matched patients (24/53) had a PFS2/PFS1 ratio ≥1.3 compared with 19.3% of patients (11/57) in the unmatched group (P = 0.004 univariable and P ≥ 0.057 in multivariable/propensity score analysis). Patients with a “matching-score” (the number of matched drugs divided by the number of aberrations; unmatched patients had a score of zero) > 0.2 had a median overall survival (OS) of 15.7 months compared with 10.6 months when their matching-score was ≤ 0.2, (P = 0.040 in the Cox regression model). Matched versus unmatched patients had higher rates of SD ≥ 6 months/PR/CR and longer PFS, and improvement in OS correlated with a higher matching score in multivariable analysis. Mol Cancer Ther; 15(4); 743–52. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-15-0795

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 182

Metadata

Authors
Schwaederle, M., Parker, B. A., Schwab, R. B., Daniels, G. A., Piccioni, D. E., Kesari, S., Helsten, T. L., Bazhenova, L. A., Romero, J., Fanta, P. T., Lippman, S. M., & Kurzrock, R.
Venue
Molecular Cancer Therapeutics
Published
2016-04-01
Volume
15
Issue
4
Pages
743-752
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2276287001
Cited by
182
References
8
FWCI
8.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. https://app.cochat.ai/papers/10.1158/1535-7163.mct-15-0795
The paper
Schwaederle, M., Parker, B. A., Schwab, R. B., Daniels, G. A., Piccioni, D. E., Kesari, S., Helsten, T. L., Bazhenova, L. A., Romero, J., Fanta, P. T., Lippman, S. M., & Kurzrock, R. (2016). Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-15-0795

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.